References
- Pieters R, Hunger SP, Boos J, et al. L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase. Cancer 2011;117:238–249.
- Stock W, Douer D, DeAngelo DJ, et al. Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents:recommendations of an expert panel. Leuk Lymphoma 2011;52:2237–2253.
- Truelove E, Fielding AK, Hunt BJ. The coagulopathy and thrombotic risk associated with L-asparaginase treatment in adults with acute lymphoblastic leukemia. Leukemia 2013;27:553–559.
- Castaman G, Rodeghiero F. Erwinia- and E. coli-derived L-asparaginase have similar effects on hemostasis. Pilot study in 10 patients with acute lymphoblastic leukemia. Haematologica 1993;78(Suppl.):57–60.
- Nocentini F, Gugliotta L, Catani L, et al. Irrelevant hemostatic toxicity of Erwinase at intermediate dose in adult patients with acute lymphoblastic leukemia: preliminary data. Haematologica 1994; 79:546–549.
- Carlsson H, Stockelberg D, Tengborn L, et al. Effects of Erwinia-asparaginase on the coagulation system. Eur J Haematol 1995;55: 289–293.
- Vignetti M, Fazi P, Cimino, G, et al. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome–positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) LAL0201-B protocol. Blood 2007;109:3676–3678.
- Foà R, Vitale A, Vignetti M, et al. Dasatinib as first-line treatment for adult patients with Philadelphia cromosome-positive acute lymphoblastic leukemia. Blood 2011;118:6521–6528.
- Bassan R, Rossi G, Pogliano EM, et al. Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with philadelphia chromosome-positive acute lymphoblastic leukemia:Northern Italy Leukemia Group Protocol 09/00. J Clin Oncol 2010;28:3644–3652.
- Duval M, Suciu S, Ferster A, et al. Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial. Blood 2002;99:2734–2739.
- Moghrabi A, Levy DE, Asselin B, et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood 2007;109:896–904.
- Kwok CS, Kham SK, Ariffin H, et al. Minimal residual disease MRD measurement as a tool to compare the efficacy of chemotherapeutic drug regimens using Escherichia coli-asparaginase or Erwinia-asparaginase in childhood acute lymphoblastic leukemia ALL. Pediatr Blood Cancer 2006;47:299–304.
- Asselin BL. The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia. Adv Exp Med Biol 1999;457: 621–629.
- Vieira Pinheiro JP, Ahlke E, Nowak-Gottl U, et al. Pharmacokinetic dose adjustment of Erwinia asparaginase in protocol II of the paediatric ALL/NHL-BFM treatment protocols. Br J Haematol 1999;104:313–320.
- Plourde PV, Jeha S, Hijiya N, et al. Safety profile of asparaginase Erwinia chrysanthemi in a large compassionate-use trial. Pediatr Blood Cancer 2014;61:1232–1238.
- Larson RA, Fretzin MH, Dodge RK, et al. Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia. Leukemia 1998;12:660–665.
- Hunault-Berger M, Chevallier P, Delain M, et al. Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome:the CAPELAL study. Haematologica 2008;93:1488–1494.
- Douer D. Is asparaginase a critical component in the treatment of acute lymphoblastic leukemia? Best Pract Res Clin Haematol 2008;21:647–658.